

Anti-Tim-3 [2C12] Standard Size Ab01057-6.4

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Rat IgG1, [Fc Silent™](#), Kappa

Clone Number: 2C12

Alternative Name(s) of Target: CD366; HAVcr-2; HAVCR2; Hepatitis A virus cellular receptor 2 homolog; T-cell immunoglobulin and mucin domain containing 3; T-cell immunoglobulin and mucin domain-containing protein 3; T-cell immunoglobulin mucin receptor 3; T-cell membrane protein 3; TIM-3; TIMD-3; TIM3; 8B.2C12

UniProt Accession Number of Target Protein: Q8VIM0

Published Application(s): Blocking, therapeutic, FC, IF, IHC

Published Species Reactivity: Mouse

Immunogen: This antibody was raised by immunising rats with TIM-3:Ig fusion protein emulsified in complete Freund's adjuvant.

Specificity: This antibody is specific for murine TIM-3, a Th1-specific cell surface protein. TIM-3 is a type I transmembrane protein and contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. This antibody binds to the BALB/c allele of TIM-3 while reactivity to the C57Bl/6 allele is significantly weaker.

Application Notes: This antibody was used in FACS, immunohistochemistry, immunofluorescence and a murine experimental autoimmune encephalomyelitis model to study the effects of TIM-3 triggering in dendritic cells (Anderson et al., 2007; PMID: 18006747). Furthermore, this antibody has been used in multiple FACS analyses for diverse immuno-oncological applications, such as to delineate how TIM-3 signaling on cells of the innate immune system critically influences regulation of the adaptive immune response (Frisancho-Kiss et al., 2006), to demonstrate the reversal of T cell exhaustion and restoration of anti-tumor immunity upon co-targeting Tim-3 and PD-1 pathways (Sakuishi et al., 2010; PMID: 20819927), and to examine the therapeutic potential of dendritic cell based vaccines against malignant glioma (Dey et al., 2015). This antibody has also been used in immunohistochemistry to aid the elucidation of the effects of Th2 immune deviation on corneal allograft survival and possible mechanisms of graft rejection (Beauregard et al., 2005). In addition, employing this anti-TIM-3 antibody as part of the combination immunotherapy (anti-TIM3 + anti-PD-1 +/- anti-CTLA-4) has been shown to be effective against experimental and carcinogen-induced tumors in mice (Sakuishi et al., 2010; PMID: 20819927) (Ngiow et al., 2011; PMID: 21430066).

Antibody First Published in: Monney et al. Th1-specific cell surface protein Tim-3 regulates macrophage

activation and severity of an autoimmune disease. Nature. 2002 Jan 31;415(6871):536-41. doi: 10.1038/415536a. [PMID:11823861](#)

Note on publication: The original publication explores the role of Tim-3 in regulating macrophage activation and influencing the severity of Th1-dependent autoimmune diseases.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.